To the full analysis
JD Health International stock: growth
6618.HKJD Health International reported $11.01B in revenue for fiscal 2025, up 26.3% on the prior year, up 30.5% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
38.1%
per year from 2017 to 2025, per share 37.7%
Earnings (Annual rate)
53.1%
per year from 2017 to 2025, per share 52.6%
Free cash flow (Annual rate)
108.3%
per year from 2017 to 2025, per share 107.8%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2017 | |
|---|---|---|
| Revenue | 30.5% | 38.1% |
| Revenue per share | 21.2% | 37.7% |
| Earnings | no data | 53.1% |
| Earnings per share | no data | 52.6% |
| Free cash flow | 21.5% | 108.3% |
| Free cash flow per share | 12.8% | 107.8% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2017 | $832.77M | $26.77M | $4.12M |
| 2018 | $1.23B | $32.23M | $27.71M |
| 2019 | $1.63B | −$145.74M | $60.63M |
| 2020 | $2.91B | −$2.58B | $552.43M |
| 2021 | $4.6B | −$160.99M | $439.17M |
| 2022 | $7.01B | $57M | $879.54M |
| 2023 | $8.03B | $321.2M | $680.15M |
| 2024 | $8.72B | $624.13M | $642.75M |
| 2025 | $11.01B | $806.12M | $1.46B |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 13 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = HK$7.8782, $1 = CN¥6.6683)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 4 Nov 2026)
- Valuation signal Undervalued since 12 Nov 2026, previously Fairly valued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.